Robert L Burr Form 4 Amneal Pharmaceuticals / ROBERT L BURR ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

BURR ROBERT L

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD, THIRD FLOOR

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2018

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/04/2018		A		60,475	A	(1)	60,475	D
Class A Common Stock	05/04/2018		A		6,057	A	(2)	6,057	I	By the Robert L. Burr IRA Account

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$16.4	05/04/2018		A		10,575		(3)	05/16/2027	Class A Common Stock	10,575	(4)	10,575	D
Stock Option	$30.33	05/04/2018		A		10,575		(3)	05/17/2026	Class A Common Stock	10,575	(4)	10,575	D
Stock Option	$44.85	05/04/2018		A		7,300		(3)	05/12/2025	Class A Common Stock	7,300	(4)	7,300	D
Stock Option	$25.24	05/04/2018		A		11,500		(3)	05/14/2024	Class A Common Stock	11,500	(4)	11,500	D
Stock Option	$17.99	05/04/2018		A		12,000		(3)	05/15/2023	Class A Common Stock	12,000	(4)	12,000	D
Stock Option	$20.9	05/04/2018		A		10,000		(3)	05/23/2022	Class A Common Stock	10,000	(4)	10,000	D
Stock Option	$27.97	05/04/2018		A		10,000		(3)	05/11/2021	Class A Common Stock	10,000	(4)	10,000	D
Stock Option	$20.3	05/04/2018		A		10,000		(3)	05/26/2020	Class A Common Stock	10,000	(4)	10,000	D
Stock Option	$6.55	05/04/2018		A		30,000		(3)	05/20/2019	Class A Common Stock	30,000	(4)	30,000	D
Stock Option	$15.01	05/07/2018		A		24,977		(5)	05/07/2028	Class A Common Stock	24,977	$0.00	24,977	D
Restricted Stock Units	(6)	05/07/2018		A		6,107		(7)	(7)	Class A Common Stock	6,107	$0.00	6,107	D

Explanation of Responses:

1. Received in exchange for 60,475 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA").

2. Received in exchange for 6,057 shares of Impax common stock pursuant to the BCA.

3. The option is vested and currently exercisable.

4. Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock.

5. The option vests in four equal annual installments beginning on May 07, 2019.

6. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

7. The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.

Remarks:

	/s/ Bryan M. Reasons, Attorney-in-Fact	05/08/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.